Biotech News
Related news
MGTXMeiraGTx2026-11-12 13:00 EST
MeiraGTx Reports Third Quarter 2026 Financial and Operational Results
CRSPCRISPR Therapeutics2026-11-10 13:30 EST
CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
NTLAIntellia2026-11-10 13:00 EST
Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London
CRSPCRISPR Therapeutics2026-11-09 14:16 EST
CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026
BCRXBioCryst Pharmaceuticals2026-11-04 21:01 EST
BioCryst to Present at Upcoming Investor Conferences
CRBUCaribou2026-11-04 14:00 EST
Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting
VYGRVoyager Therapeutics2026-10-27 12:01 EST
Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026
MGTXMeiraGTx2026-10-27 12:00 EST
MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting
RCKTRocket Pharmaceuticals2026-10-15 11:00 EST
Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference
TARAProtara Therapeutics2026-09-08 20:05 EST
Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
MeiraGTx
Genetic Medicines Company MeiraGTx develops and manufactures gene therapies for inherited retinal disease, salivary-gland disorders, and other conditions. Its vertically integrated model spans vector design, clinical development, and commercial manufacturing. Bota-Vec Botaretigene sparoparvovec is an AAV gene therapy for X-linked...
Recent company news
MGTXMeiraGTx2026-11-16 12:00 EST
MeiraGTx Announces Oral Presentation at ObesityWeek 2026
MGTXMeiraGTx2026-11-12 13:00 EST
MeiraGTx Reports Third Quarter 2026 Financial and Operational Results
MGTXMeiraGTx2026-10-27 12:00 EST
MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting
MGTXMeiraGTx2026-09-23 12:00 EST
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
MGTXMeiraGTx2026-08-13 12:00 EST
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
Stock data
- Close
- 8.14 USD
- Market cap
- 855.71M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
